The option program 2021/24 for Nanologica AB resolved by the Annual General Meeting 2021 has now been implemented. The program was subscribed at 100 percent by both the management team, including the CEO, and employees. At the Annual General Meeting on May 27, 2021, a new stock option program was resolved, which has now been implemented. In option program 2021/24 for Nanologica's management and employees, 800,000 of the total 800,000 options have been subscribed for.
Nanologica has recruited Katarina Alenäs as VP Chromatography to lead Nanologica's sales organization within Chromatography globally. As sales start for preparative chromatography approaches, Nanologica's sales organization is now strengthened with Katarina Alenäs as VP Chromatography. The assignment includes leading the sales organization and driving the work globally. Nanologica thus has its own sales organization covering all major markets – India, China, US and Europe. " With solid experience from the biotechnology industry in general and
In accordance with the decision taken at the annual general meeting on May 27, 2021, the three largest shareholders as of September 30, 2021 have been contacted by the chairman of the board and been offered to appoint a member each to the nomination committee of Nanologica AB. The three largest shareholders as of September 30, 2021 have each appointed one representative so that the nomination committee for the annual general meeting 2022 consists of
Nanologica AB has decided to close the project with the drug candidate NIC-001 for the treatment of gastroparesis before the planned clinical study begins, in order to focus the company's resources on the continued development of the inhalation platform NLAB Spiro®. The closure of the project is a result of the company's strategy in the drug development business area being refined to focus on inhalation and respiratory diseases, and because the commercial conditions for NIC-001
Nanologica has recruited Gary Pitcairn as Chief Scientific Officer as part of the strategy to increase the focus on inhalation and respiratory diseases, as well as to accelerate the development of the company's technology platform for inhalation, NLAB Spiro®. Nanologica is exploring new possibilities within inhalation and respiratory diseases and has recruited Gary Pitcairn as the company's first Chief Scientific Officer. Gary, who during 2021 has been one of Nanologica's scientific advisors for inhalation, will
Nanologica has completed the first study within the tox program for the inhalation platform NLAB Spiro®. The program now continues with further studies. NLAB Spiro® is Nanologica’s technology platform for inhalation. To validate the safety of the platform, toxicity studies are conducted in several steps and the first study has now been completed. Results from the sub-study are expected to be presented during the third quarter. During the second half of the year, the program